Immunocore director granted 27,492 stock options

Immunocore Holdings plc director Siddharth Kaul received a grant of share options for 27,492 ordinary shares.

Rhea-AI Filing Summary

Immunocore Holdings plc director Siddharth Kaul received a grant of share options for 27,492 ordinary shares. The options carry an exercise price of $28.52 per share and expire on May 26, 2036, providing long-term equity-based compensation.

The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, as long as Kaul remains in continuous service until that vesting date. This is a compensation-related grant, not an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 27,492 shares

Grant/Award 1 txn

Insider Kaul Siddharth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	27,492	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 27,492 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 27,492 options Exercise price: $28.52 per share Expiration date: May 26, 2036 +2 more

5 metrics

Options granted 27,492 options Share Option (Right to Buy) granted to director

Exercise price $28.52 per share Exercise price of granted share options

Expiration date May 26, 2036 Option term end date

Underlying shares 27,492 ordinary shares Shares subject to the option award

Post-grant derivative holdings 27,492 options Total options held following this transaction

Key Terms

Share Option (Right to Buy), Ordinary Shares, exercise price, annual general meeting, +1 more

5 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"conversion_or_exercise_price: "28.5200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual general meeting financial

"the date of the Issuer's next annual general meeting"

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Immunocore (IMCR) disclose for Siddharth Kaul?

Immunocore reported a grant of share options to director Siddharth Kaul. He received options for 27,492 ordinary shares as equity-based compensation, with no cash paid per option at grant and an exercise price set at $28.52 per share.

How many Immunocore (IMCR) options were granted to Siddharth Kaul and at what price?

Siddharth Kaul was granted 27,492 share options in Immunocore. Each option allows him to buy one ordinary share at an exercise price of $28.52, aligning his compensation with future share price performance over the option term.

When do Siddharth Kaul’s Immunocore (IMCR) option awards vest?

The option award vests on the earlier of two potential dates. Vesting occurs on May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided Kaul remains in continuous service through the applicable vesting date.

What is the expiration date of Siddharth Kaul’s Immunocore (IMCR) share options?

The granted share options expire on May 26, 2036. After this date, any unexercised options will lapse. The long duration gives Kaul a substantial window to exercise the options if Immunocore’s share price exceeds the $28.52 exercise price.

Is Siddharth Kaul’s Immunocore (IMCR) Form 4 transaction a market buy or sell?

The Form 4 reports a grant of options, not a market trade. The transaction is classified as a grant or award acquisition, meaning it reflects equity compensation rather than Kaul buying or selling Immunocore shares in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 07:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaul Siddharth

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON OXFORDSHIRE OX14 4RY

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$28.52	05/27/2026		A		27,492		(1)	05/26/2036	Ordinary Shares	27,492	$0	27,492	D

Explanation of Responses:

1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)